Medical/Pharmaceuticals
NDA Filing for Luye Pharma's Antidepressant Drug LY03005 Accepted by the U.S. FDA
SHANGHAI, March. 4, 2020 /PRNewswire/ -- Luye Pharma Group has announced that the U.S. Food and Drug Administration (FDA) has reviewed and accepted the filing of a New Drug Application (NDA) for LY03005, a new chemical drug for the treatment of major depressive disorder. LY03005 is the company's ...
2020-03-04 21:27
2111
China Biologic Products to Report Fourth Quarter and Fiscal Year 2019 Financial Results
BEIJING, March 3, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its fourth quarter and fiscal year 2019 fi...
2020-03-03 21:30
7821
Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drug
SONGDO, South Korea, March 2, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and STCube announced a strategic development and manufacturing service agreement for STT-003 antibody, an anti-cancer drug candidate. Under the agreement, Samsung Biologics will offer a wide range of services from c...
2020-03-03 03:00
1269
Yuyu Pharma announces review of compliance policies and procedures
SEOUL, South Korea, March 2, 2020 /PRNewswire/ -- Yuyu Pharma (COO Robert Wonsang Yu, KRX 000220) announced today a review of its compliance policies and procedures with the support of the law firm, Kim & Chang. The Kim & Chang project team, consisting of 6 lawyers and 1 expert advisor, implement...
2020-03-02 22:00
1232
China Pharmaceutical Holdings Co., Ltd. Launched A New Product
HAIKOU CITY, China, March 2, 2020 /PRNewswire/ -- China Pharmaceutical Holdings Limited (NYSE American: CPHI) ("China Pharma" or "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that its subsidiary, Hainan ...
2020-03-02 20:00
6036
3SBIO makes investment in MPM's $100M Oncology Innovations Fund and donation to Dana-Farber cancer research
SHANGHAI, March 1, 2020 /PRNewswire/ -- MPM Capital (MPM) and Dana-Farber Cancer Institute have jointly announced onFebruary 26, 2020 the successful closing of the MPM Oncology Innovations Fund (INV) with$100M in capital, and the Dana-Farber Innovations Research Fund (IRF) with more than$26M in p...
2020-03-01 16:30
1547
Samsung Biologics Confirms 'No Impact' of COVID-19 with Business Continuity Plan in Effect
SONGDO, South Korea, Feb. 24, 2020 /PRNewswire/ -- Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations. The company confi...
2020-02-27 15:49
1555
WuXi Diagnostics' integrated testing solution for COVID-19 epidemiological investigation and diagnosis
SHANGHAI, Feb. 27, 2020 /PRNewswire/ -- WuXi Diagnostics has successfully developed a series of COVID-19 detection products, including2019-nCoV IgM Detection kit (Enzyme-linked Immunoassay, ELISA), 2019-nCoV IgM/IgG Detection Kit (Enzyme-linked Immunoassay, ELISA) and 2019-nCoV Nucleic Acid Detec...
2020-02-27 15:47
1919
New Data Confirms Cardiac Dimensions' Carillon® System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation
Pooled Analysis of Prospective Studies Presented during Late Breaking Trials Session at CRT 2020 KIRKLAND, Washington, Feb. 25, 2020 /PRNewswire/ -- Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients ...
2020-02-26 00:50
1166
United Imaging's Emergency Radiology Departments Support Mobile Cabin Hospitals, Facilitate 5G Remote Diagnosis
SHANGHAI, Feb. 25, 2020 /PRNewswire/ -- At the center of the epidemic in Wuhan, many sports centers, exhibition halls, and schools have been turned into mobile cabin hospitals (MCHs) to treat tens of thousands of coronavirus patients with mild symptoms. During the epidemic, fast and accurate CT d...
2020-02-25 21:00
1769
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Trial of APG-1387 in Combination with Chemotherapy for the Treatment of Advanced Pancreatic Cancer in China
SUZHOU, China and ROCKVILLE, MD., Feb. 24, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has receive...
2020-02-24 22:00
2426
Emergency Service from 111 Helps Companies Secure Epidemic Supplies to Open for Business
SHANGHAI, Feb. 24, 2020 /PRNewswire/ -- Businesses across China need to secure epidemic supplies such as face masks and disinfectant to re-open factories and offices. Now they will be able to turn to 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthca...
2020-02-24 16:00
4249
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321
SHANGHAI, Feb. 23, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its strategic partner Immutep, a biotechnology comp...
2020-02-24 08:00
6137
VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update
AUSTIN, Texas, Feb. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year endedDecember 31, 2019. Volition management will host a conference call tomorrow,February 21, at 8:30 a.m. U.S. Easte...
2020-02-21 05:10
10107
StoneWise AI-driven Drug Discovery Platform: Investigation and Repurpose of Nucleoside-based RNA Polymerase Inhibitors and Their Potential Use in COVID-19 Infection Treatment
BEIJING, Feb. 20, 2020 /PRNewswire/ -- In a campaign to screen drugs for the treatment of COVID-19, the disease caused by SARS-CoV-2, StoneWise, a company specialized in applying artificial intelligence to innovative drug design solutions for innovative drug R&D enterprises and institutions, has ...
2020-02-20 20:04
1413
111 Partners with Financial Institutions in Battle Against Coronavirus
SHANGHAI, Feb. 20, 2020 /PRNewswire/ -- 111, Inc. (NASDAQ: YI, "111" or the "Company") has announced that it will leverage its knowhow and technology in the battle against the novel coronavirus (COVID-19) public health crisis, through partnerships with some ofChina's leading financial institution...
2020-02-20 17:00
5341
Ten billion investment to build Chengdu medical city to create a new highland for the international health industry
CHENGDU, China, Feb. 20, 2020 /PRNewswire/ -- In 2019, with the continuous advancement of "three medical integration", Chengdu Medical City's three medical innovation center, as "Western China Biomedical Innovation Center", submitted a satisfactory answer sheet: 58 new contracted projects (47 thr...
2020-02-20 16:04
770
VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunctio...
2020-02-19 05:10
10246
Transcenta Achieves Major Milestone in Continuous Perfusion Cell Culture Platform to Provide Industry Leading Productivity and Speed to Manufacturing
SUZHOU and HANGZHOU, China, Feb. 18, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D, regulatory affairs and manufacturing, today announced it has achieved a major milestone in its continuous perfusion cell cult...
2020-02-19 00:00
756
Henlius successfully held its fourth Scientific Advisory Board (SAB) meeting
SHANGHAI, Feb. 18, 2020 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK, Henlius), a global biologics company specialized in the discovery and development of high-quality and affordable antibodies for the treatment of patients with cancer and autoimmune diseases, recently held its fourth ...
2020-02-18 21:59
6513
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5310
